Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT03294434 : Predicting Sites of Tumour Progression in the Invasive Margin of Glioblastomas (PRaM-GBM Study)
AgesMin: 16 Years Max: 75 Years
Inclusion Criteria:

- Have given written informed consent to participate

- Assessed by a neuroscience MDT to have a high grade glioma on imaging, OR if in the
opinion of the CI, with guidance from the local PI that all relevant and appropriate
members of a multidisciplinary team agree a high grade glioma diagnosis;

- Considered suitable for radical radiotherapy (60 Gy) with concomitant chemotherapy
(Stupp Regime);

- WHO PS 0 or 1 (see Appendix 3);

- Age 16 - 75;

- Patient suitable for tumour resection where the treating neurosurgeon feels that >90%
of the enhancing tumour will be resected;

Exclusion Criteria:

- Patients who are participating in trials involving investigational treatments

- Patients who are unsuitable for a contrast-enhanced MRI will be excluded. Such
clinical problems include, but are not limited to:

- MR unsafe metallic implants;

- Claustrophobia;

- Allergy to gadolinium contrast agent;

- History of severe renal impairment.

- Patients unable to provide written informed consent

- PET sub-study only: Pregnant women
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557